An act to add Article 16 (commencing with Section 111224.8) to Chapter 5 of Part 5 of Division 104 of the Health and Safety Code, relating to public health. health, and making an appropriation therefor.
AB 1088 would create a new “Kratom Consumer Protection Program” within California’s Sherman Food, Drug, and Cosmetic Law. It defines kratom products and products containing 7-hydroxymitragynine (7-OH), sets limits on the amount of 7-hydroxymitragynine allowed in kratom products, and establishes packaging and labeling rules. The bill also bars products that are marketed in ways that are attractive to children, requires child-resistant packaging, and directs online sellers to use age-verification systems.
The bill would prohibit the sale, offer for sale, distribution, or provision of kratom products and 7-OH products to anyone under 21. It also would exempt producers and sellers of these products from any requirement to register with or seek licensure from the State Department of Public Health under the cited provisions of the Sherman Law. Because the bill expands criminal enforcement under the food and drug law, it is treated as creating a state-mandated local program, though the bill states no reimbursement is required.
AB 1088 would add a new article to the Health and Safety Code governing kratom and 7-OH products, bringing them under the state’s food, drug, and cosmetic regulatory framework for purposes of packaging, labeling, youth access, and product composition. It would create enforceable restrictions on manufacturers, retailers, and online marketplaces, while also carving out an exemption from department registration/licensure requirements for these products. The bill would affect kratom producers, distributors, retailers, and marketplaces, and could expose violators to criminal penalties under the Sherman Law.
The available voting history suggests broad support for the bill at each stage it moved, with unanimous committee votes and a 76-0 Assembly third reading vote. That pattern indicates the measure was generally viewed favorably as a consumer-protection and youth-safety bill. The lack of recorded committee transcript discussion limits insight into detailed arguments, but the procedural history shows little visible opposition in the recorded votes.
The main policy tension appears to be between consumer protection and regulation of a legal herbal product. Supporters likely favor the bill’s age restrictions, child-resistant packaging, and limits on child-appealing marketing as safeguards against youth access and unsafe formulations. Potential concerns, though not reflected in recorded opposition votes, would center on whether the bill overregulates kratom, how the 7-hydroxymitragynine cap is set and enforced, and whether exempting sellers from registration/licensure undercuts oversight even as the bill imposes new restrictions.